Livmoniplimab + Budigalimab for Liver Cancer

(LIVIGNO-2 Trial)

Recruiting in Palo Alto (17 mi)

+41 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: AbbVie

Disqualifiers: Prior systemic therapy, CNS metastases, others

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial tests a new treatment combining two drugs, livmoniplimab and budigalimab, for adults with advanced liver cancer. The goal is to find the best dose and check for side effects and effectiveness. The treatment helps the immune system fight cancer cells.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug Budigalimab in treating liver cancer?

Budigalimab, an anti-PD-1 inhibitor, has shown safety and effectiveness in treating other cancers like non-small cell lung cancer and head and neck squamous cell carcinoma, suggesting potential for similar effects in liver cancer. ^{1 2 3 4 5}

What makes the drug Livmoniplimab + Budigalimab unique for liver cancer?

Livmoniplimab + Budigalimab is unique because it combines two monoclonal antibodies (lab-made proteins that can bind to specific targets in the body) to potentially enhance the immune system's ability to fight liver cancer, which is different from traditional chemotherapy or targeted therapies that directly attack cancer cells. ^{6 7 8 9 10}

Research Team

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

Adults with advanced liver cancer (HCC) that can't be surgically removed or has spread, confirmed by tests or clinical criteria. They should have a certain level of liver function (Child-Pugh A or B7) and be able to perform daily activities with little to no assistance (ECOG 0-1).

Inclusion Criteria

I am fully active or can carry out light work.

My liver cancer cannot be removed by surgery and is confirmed by tests or clinical criteria.

My liver cancer is at an intermediate or advanced stage.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment - Stage 1

Participants receive treatment in one of three arms: livmoniplimab with budigalimab, atezolizumab with bevacizumab, or tremelimumab with durvalumab. Treatment is administered every 3 or 4 weeks depending on the arm.

Until disease progression or discontinuation criteria are met

Regular visits every 3-4 weeks

Treatment - Stage 2

Participants receive treatment in one of two arms: livmoniplimab with budigalimab or tremelimumab with durvalumab. Treatment is administered every 3 or 4 weeks depending on the arm.

Until disease progression or discontinuation criteria are met

Regular visits every 3-4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Budigalimab (Checkpoint Inhibitor)
• Livmoniplimab (Checkpoint Inhibitor)

Trial Overview The trial is testing different doses of Livmoniplimab combined with Budigalimab against other treatments like Atezolizumab/Bevacizumab and Tremelimumab/Durvalumab in adults with HCC. Participants are randomly assigned to these groups and treated every few weeks until disease progression.

Participant Groups

Group I: Stage 2: Arm 1 Experimental Treatment 2 Interventions

Participants will receive livmoniplimab (optimized dose) in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.

Group II: Stage 1: Cohort 2 Experimental Treatment 2 Interventions

Participants will receive livmoniplimab Dose 2 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.

Group III: Stage 1: Cohort 1 Experimental Treatment 2 Interventions

Participants will receive livmoniplimab Dose 1 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.

Group IV: Stage 2: Arm 2 (Control) Active Control 2 Interventions

Participants will receive a single dose of tremelimumab in combination with durvalumab every 4 weeks until disease progression or until discontinuation criteria are met.

Group V: Stage 1: Cohort 3 - Group 1 (Control) Active Control 2 Interventions

Participants will receive atezolizumab in combination with bevacizumab every 3 weeks until disease progression or until discontinuation criteria are met.

Group VI: Stage 1: Cohort 3 - Group 2 (Control) Active Control 2 Interventions

Participants will receive a single dose of tremelimumab in combination with durvalumab every four weeks until disease progression or until discontinuation criteria are met.

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Findings from Research

In a phase I/II study involving 219 patients with advanced solid tumors, the combination of sabatolimab and spartalizumab was well tolerated, with fatigue being the most common treatment-related side effect.

While no responses were observed with sabatolimab alone, the combination treatment showed preliminary antitumor activity, with 5 patients achieving partial responses in various cancers, suggesting potential efficacy in specific populations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Curigliano, G., Gelderblom, H., Mach, N., et al.[2023]

Budigalimab, a monoclonal antibody targeting PD-1, demonstrated a safety profile similar to other PD-1 inhibitors, with the most common severe side effect being anemia in 22% of HNSCC patients and 13% of NSCLC patients.

In terms of efficacy, budigalimab showed objective response rates of 13% in head and neck squamous cell carcinoma (HNSCC) and 19% in non-small cell lung cancer (NSCLC), with median progression-free survival of 3.6 months and 1.9 months, respectively, indicating it may be a viable treatment option for these cancers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano, A., Cassier, PA., Lin, CC., et al.[2023]

Abagovomab, an anti-idiotypic antibody targeting CA-125, was found to be safe and well tolerated in a phase I trial with 36 patients, showing no treatment-limiting toxicities and only mild local injection site reactions.

The longer vaccination schedule (nine injections) led to a higher frequency of CA-125 specific CD8+ T-cells and successful induction of immune responses in all evaluable patients, suggesting it may be more effective than the shorter schedule.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Pfisterer, J., du Bois, A., Sehouli, J., et al.[2020]

Tremelimumab, an immune checkpoint inhibitor targeting CTLA-4, can lead to significant tumor shrinkage in solid tumors, even after initial rapid disease progression, as seen in two case studies involving bile duct cancer and squamous cell carcinoma.

Remarkably, these responses occurred without any immune-related adverse events, indicating a potentially safe profile for tremelimumab in cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tremelimumab-associated tumor regression following after initial progression: two case reports. Shimomura, A., Fujiwara, Y., Kondo, S., et al.[2019]

M2BPGi is identified as a strong short-term predictor of hepatocellular carcinoma (HCC) in untreated chronic hepatitis B patients, with a significant odds ratio of 7.40 for predicting HCC within 1-2 years for those with elevated levels.

In a study of 1070 samples, M2BPGi, along with α-fetoprotein (AFP) and hepatitis B surface antigen (HBsAg), were found to be independent predictors of HCC, demonstrating the potential of M2BPGi in early detection of this cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Liu, J., Hu, HH., Lee, MH., et al.[2019]

References

1. United States pubmed.ncbi.nlm.nih.gov

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. [2023]

2. Germany pubmed.ncbi.nlm.nih.gov

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. [2023]

3. England pubmed.ncbi.nlm.nih.gov

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. [2020]

4. England pubmed.ncbi.nlm.nih.gov

Tremelimumab-associated tumor regression following after initial progression: two case reports. [2019]

5. England pubmed.ncbi.nlm.nih.gov

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. [2022]

6. England pubmed.ncbi.nlm.nih.gov

Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. [2019]

7. Australia pubmed.ncbi.nlm.nih.gov

Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. [2020]

8. Switzerland pubmed.ncbi.nlm.nih.gov

On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy. [2020]

9. Switzerland pubmed.ncbi.nlm.nih.gov

Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. [2022]

10. Korea (South) pubmed.ncbi.nlm.nih.gov

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. [2021]